HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

A prospective, randomised double-blind crossover study to examine the efficacy of strontium-89 in pain palliation in patients with advanced prostate cancer metastatic to bone.

Abstract
The palliative efficacy of strontium-89 chloride has been evaluated in a prospective double-blind crossover study comparing it with stable strontium as placebo in 32 patients with prostate cancer metastatic to bone. Response was assessed 5 weeks after each treatment. 26 patients were evaluable. Complete pain relief was only reported following strontium-89 injection. Statistical comparison between placebo and strontium-89 showed clear evidence of a therapeutic response to strontium-89 compared with only a limited placebo effect (P less than 0.01).
AuthorsV J Lewington, A J McEwan, D M Ackery, R J Bayly, D H Keeling, P M Macleod, A T Porter, M A Zivanovic
JournalEuropean journal of cancer (Oxford, England : 1990) (Eur J Cancer) Vol. 27 Issue 8 Pg. 954-8 ( 1991) ISSN: 0959-8049 [Print] England
PMID1716935 (Publication Type: Clinical Trial, Comparative Study, Journal Article, Randomized Controlled Trial)
Chemical References
  • Strontium Radioisotopes
Topics
  • Aged
  • Bone Neoplasms (radiotherapy, secondary)
  • Double-Blind Method
  • Humans
  • Male
  • Middle Aged
  • Pain (prevention & control)
  • Palliative Care
  • Platelet Count (radiation effects)
  • Prospective Studies
  • Prostatic Neoplasms (radiotherapy)
  • Strontium Radioisotopes (therapeutic use)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: